These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1206 related items for PubMed ID: 18202419

  • 1. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
    Culine S, Kramar A, Théodore C, Geoffrois L, Chevreau C, Biron P, Nguyen BB, Héron JF, Kerbrat P, Caty A, Delva R, Fargeot P, Fizazi K, Bouzy J, Droz JP, Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
    J Clin Oncol; 2008 Jan 20; 26(3):421-7. PubMed ID: 18202419
    [Abstract] [Full Text] [Related]

  • 2. Experience with bleomycin, etoposide, cisplatin (BEP) and alternating cisplatin, cyclophosphamide, doxorubicin (CISCA(II))/vinblastine, bleomycin (VB(IV)) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors.
    Culine S, Théodore C, Bekradda M, Farhat F, Terrier-Lacombe MJ, Droz JP.
    Am J Clin Oncol; 1997 Apr 20; 20(2):184-8. PubMed ID: 9124197
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial.
    Fizazi K, Do KA, Wang X, Finn L, Logothetis CJ, Amato RJ.
    Ann Oncol; 2002 Jan 20; 13(1):125-34. PubMed ID: 11863094
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
    Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, Bajorin DF, Lara PN, Einhorn L, Mazumdar M, Bosl GJ.
    J Clin Oncol; 2007 Jan 20; 25(3):247-56. PubMed ID: 17235042
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.
    Cushing B, Giller R, Cullen JW, Marina NM, Lauer SJ, Olson TA, Rogers PC, Colombani P, Rescorla F, Billmire DF, Vinocur CD, Hawkins EP, Davis MM, Perlman EJ, London WB, Castleberry RP, Pediatric Oncology Group 9049, Children's Cancer Group 8882.
    J Clin Oncol; 2004 Jul 01; 22(13):2691-700. PubMed ID: 15226336
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Evaluation of long-term results of a modified VAB-6 chemotherapy regimen in a cohort of good-risk metastatic non seminomatous germ-cell tumors.
    Culine S, Philippot I, Farhat F, Théodore C, Terrier-Lacombe MJ, Droz JP.
    Bull Cancer; 1997 Apr 01; 84(4):368-72. PubMed ID: 9238159
    [Abstract] [Full Text] [Related]

  • 14. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial.
    Droz JP, Kramar A, Biron P, Pico JL, Kerbrat P, Pény J, Curé H, Chevreau C, Théodore C, Bouzy J, Culine S, Genito-Urinary Group of the French Federation of Cancer Centers (GETUG).
    Eur Urol; 2007 Mar 01; 51(3):739-46; discussion 747-8. PubMed ID: 17084512
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
    Fizazi K, Prow DM, Do KA, Wang X, Finn L, Kim J, Daliani D, Papandreou CN, Tu SM, Millikan RE, Pagliaro LC, Logothetis CJ, Amato RJ.
    Br J Cancer; 2002 May 20; 86(10):1555-60. PubMed ID: 12085204
    [Abstract] [Full Text] [Related]

  • 18. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K, Pagliaro L, Laplanche A, Fléchon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Culine S.
    Lancet Oncol; 2014 Dec 20; 15(13):1442-1450. PubMed ID: 25456363
    [Abstract] [Full Text] [Related]

  • 19. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era.
    Sonneveld DJ, Hoekstra HJ, van der Graaf WT, Sluiter WJ, Mulder NH, Willemse PH, Koops HS, Sleijfer DT.
    Cancer; 2001 Apr 01; 91(7):1304-15. PubMed ID: 11283931
    [Abstract] [Full Text] [Related]

  • 20. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors.
    Kondagunta GV, Bacik J, Bajorin D, Dobrzynski D, Sheinfeld J, Motzer RJ, Bosl GJ.
    J Clin Oncol; 2005 Dec 20; 23(36):9290-4. PubMed ID: 16361627
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 61.